These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 27665574)

  • 41. Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson's disease: current status.
    Müller T; Möhr JD
    Expert Opin Drug Metab Toxicol; 2019 May; 15(5):429-435. PubMed ID: 31017021
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies.
    Wasan H; Singh D; Kh R
    Brain Res Bull; 2021 Mar; 168():165-177. PubMed ID: 33387637
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain.
    Cattaneo C; Kulisevsky J; Tubazio V; Castellani P
    Adv Ther; 2018 Apr; 35(4):515-522. PubMed ID: 29542008
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease.
    Cattaneo C; Müller T; Bonizzoni E; Lazzeri G; Kottakis I; Keywood C
    J Parkinsons Dis; 2017; 7(4):629-634. PubMed ID: 28777756
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson's disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies.
    Elkamhawy A; Paik S; Park JH; Kim HJ; Hassan AHE; Lee K; Park KD; Roh EJ
    Bioorg Chem; 2021 Oct; 115():105233. PubMed ID: 34390968
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review.
    Parambi DGT
    Comb Chem High Throughput Screen; 2020; 23(9):847-861. PubMed ID: 32238135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safinamide (Newron Pharmaceuticals).
    Chazot PL
    Curr Opin Investig Drugs; 2001 Jun; 2(6):809-13. PubMed ID: 11572661
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Spanish expert consensus on the use of safinamide in Parkinson's disease.
    Valldeoriola F; Grandas F; Arbelo JM; Blázquez Estrada M; Calopa Garriga M; Campos-Arillo VM; Garcia Ruiz PJ; Gómez Esteban JC; Leiva Santana C; Martínez Castrillo JC; Mir P; Salvador Aliaga A; Vivancos Matellano F; Yáñez Baña RM
    Neurologia (Engl Ed); 2021; 36(9):666-672. PubMed ID: 34752344
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Safinamide Mesilate (Equfina
    Koebisu M; Ishida T
    Nihon Yakurigaku Zasshi; 2020; 155(4):269-276. PubMed ID: 32612042
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease.
    Bianchi MLE; Riboldazzi G; Mauri M; Versino M
    Neurol Sci; 2019 Feb; 40(2):275-279. PubMed ID: 30382437
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Safinamide from daily clinical practice: first clinical steps].
    Pagonabarraga J; Kulisevsky J
    Rev Neurol; 2017 Nov; 65(10):433-438. PubMed ID: 29130466
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study.
    De Micco R; Satolli S; Siciliano M; De Mase A; Giordano A; Tedeschi G; Tessitore A
    Neurol Sci; 2022 Jan; 43(1):357-364. PubMed ID: 34031800
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emerging approaches in Parkinson's disease - adjunctive role of safinamide.
    Müller T
    Ther Clin Risk Manag; 2016; 12():1151-60. PubMed ID: 27536120
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E.
    Drugs R D; 2004; 5(6):355-8. PubMed ID: 15563241
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effects of safinamide on dysphagia in Parkinson's disease.
    Hirano M; Samukawa M; Isono C; Nagai Y
    PLoS One; 2023; 18(5):e0286066. PubMed ID: 37228084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease.
    Abbruzzese G; Barone P; Lopiano L; Stocchi F
    Drug Des Devel Ther; 2021; 15():2507-2517. PubMed ID: 34140766
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analgesic effect of safinamide mesylate in a rat model of neuropathic pain.
    Kogo Y; Koebis M; Kobayashi Y; Ishida T; Maeda T
    Behav Brain Res; 2023 Aug; 452():114555. PubMed ID: 37355233
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
    Grégoire L; Jourdain VA; Townsend M; Roach A; Di Paolo T
    Parkinsonism Relat Disord; 2013 May; 19(5):508-14. PubMed ID: 23402994
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study.
    Rinaldi D; Sforza M; Assogna F; Savini C; Salvetti M; Caltagirone C; Spalletta G; Pontieri FE
    J Neural Transm (Vienna); 2021 Feb; 128(2):273-277. PubMed ID: 33068177
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson's disease: A post hoc analysis of a Japanese phase 2/3 study.
    Nomoto M; Ishida T; Koebis M; Kamei T; Suzuki I; Hattori N; Tsuboi Y
    J Neurol Sci; 2022 Mar; 434():120083. PubMed ID: 35007919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.